Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)
This study is for people with a type of cancer called Gastrointestinal Stromal Tumour (GIST) who have been taking imatinib medicine for at least 10 years. Currently, it's not clear if people need to take imatinib forever. This study aims to find out if it's safe to stop the treatment after such a long time, or if continuing it is better for keeping the cancer under control. Patients taking part will be divided into two groups: one group will stop taking imatinib, and the other will continue. Researchers will then check how well the cancer is controlled in both groups. They will also see if imatinib still works effectively if restarted in those who stopped and whose cancer started to grow again. The goal is to understand the best treatment plan for long-term GIST patients.
Auf einen Blick
Worum geht es in dieser Studie?
This study is looking at a type of cancer called Gastrointestinal Stromal Tumour, or GIST for short. GIST often starts in the digestive system and is treated with a medicine called imatinib. This medicine has been a huge step forward for people with GIST.
Doctors know that imatinib works well to control GIST because it targets specific changes within the cancer cells. However, what they don't know for sure is whether people need to take this medicine for their entire lives, especially after many years of successful treatment. Past research has shown that stopping imatinib too early can cause the cancer to grow back quickly, but it's not clear what happens after a very long time, like 10 years.
This study aims to answer the important question of whether patients who have been on imatinib for at least 10 years can safely stop taking it. Some patients will continue with their imatinib, while others will stop. By comparing these two groups, the researchers hope to understand if stopping the medicine is a safe option for some people, or if continuing it is always the best way to keep the cancer under control. They will also collect information on whether the medicine works just as well if it's restarted after a break.
Wichtige Erkenntnisse
- This study is for people with advanced GIST who have been on imatinib for at least 10 years.
- It aims to see if stopping imatinib after a long period is safe or if continuing it is better.
- Participants will either continue imatinib or stop it, with close monitoring.
- If you stop and your cancer progresses, imatinib will be restarted to see if it still works.
- The study helps doctors understand the best long-term treatment plans for GIST.
- Sie können jederzeit von der Studie zurücktreten.
Wer könnte berechtigt sein?
To join this study, you need to be at least 18 years old and have a confirmed diagnosis of advanced GIST. This means your GIST has spread to other parts of your body or is locally advanced. Your cancer must have specific genetic changes (called c-kit mutations).
You must have been taking imatinib at a steady dose (either 300mg or 400mg per day) for 10 years or more, with only very short breaks if any. Importantly, your GIST must be well-controlled and not have grown worse while you've been on imatinib. You should also be generally well enough to take part in the study activities.
There are also reasons why you might not be able to join. For example, if you are currently taking other cancer medications, have specific types of GIST mutations (like D842V in PDGFRA), or have certain serious health problems affecting your heart, liver, or kidneys. You also can't take part if you have HIV or have had major surgery recently.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Sind Sie 18 Jahre oder älter?
- Do you have advanced GIST with a c-kit change in your cancer cells?
- Have you been taking imatinib for at least 10 years with your GIST under control?
- Are you generally well and able to attend regular clinic visits?
- Do you not have other serious long-term health conditions that might affect the study?
Was beinhaltet die Teilnahme?
If you decide to take part in this study, you will be assigned to one of two groups. One group will continue taking your imatinib as usual, and the other group will stop taking it. Your treatment plan will depend on which group you are in.
You will have regular visits to the clinic for check-ups, which will include blood tests and other assessments. These appointments are designed to monitor your health and how your cancer is responding to treatment. The doctors will monitor for any signs of the cancer returning in those who stopped treatment, and if it does, imatinib will be restarted. The study will continue for a period of time to gather enough information, and you will be informed about the specific duration of your involvement.
Potenzielle Risiken und Vorteile
Standorte (13)
- CHU BesançonVerifizierte PostleitzahlBesançon, France· Rekrutierung
- Institut BergoniéVerifizierte PostleitzahlBordeaux, Frankreich· Rekrutierung
- CHU DupuytrenVerifizierte PostleitzahlLimoges, Frankreich· Rekrutierung
- Centre Léon BérardVerifizierte PostleitzahlLyon, Frankreich· Rekrutierung
- Institut Paoli CalmettesVerifizierte PostleitzahlMarseille, Frankreich· Noch nicht rekrutiert
- Institut CurieVerifizierte PostleitzahlParis, Frankreich· Noch nicht rekrutiert
- CHU de ReimsVerifizierte PostleitzahlReims, Frankreich· Rekrutierung
- Centre Eugène MarquisVerifizierte PostleitzahlRennes, France· Noch nicht rekrutiert
- Institut de Cancérologie de l'Ouest - Site Réné GauducheauVerifizierte PostleitzahlSaint-Herblain, France· Noch nicht rekrutiert
- Institut de Cancérologie Lucien NEUWIRTHVerifizierte PostleitzahlSaint-Paul-en-Jarez, France· Noch nicht rekrutiert
- Institut Claudius RegaudVerifizierte PostleitzahlToulouse, Frankreich· Noch nicht rekrutiert
- Institut de Cancérologie de LorraineVerifizierte PostleitzahlVandœuvre-lès-Nancy, France· Noch nicht rekrutiert
Häufige Fragen
What is GIST?
GIST stands for Gastrointestinal Stromal Tumour. It's a type of cancer that usually starts in the digestive system.
What is imatinib?
Imatinib is a medicine that targets specific changes in GIST cancer cells to help control the disease. It's also known by its brand name, Glivec.
Why is this study happening?
This study wants to find out if people who have been taking imatinib for 10 years or more for GIST can safely stop the medicine, or if they need to continue taking it for longer.
Will I have to stop my medicine if I join?
Not necessarily. Patients in this study will be split into two groups – one group will stop taking imatinib, and the other will continue. You won't know which group you're in until after you join.
What if my cancer grows back if I stop the medicine?
The study design includes restarting imatinib if your cancer shows signs of coming back. The researchers want to see if the medicine is still effective at controlling the disease when restarted.
Wie Sie mehr erfahren können
Jean-Yves BLAY, Pr
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Interessiert daran, teilzunehmen?
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.